PharmaView   MAR.2007

Pharmaceutical Marketers are facing increasing pressures: increasing competition; squeezed margins; shrinking budgets; more to do and less time to do it. It’s becoming difficult to work any harder, and of course it's always better to work smarter. Therefore we bring you the PharmaView.

PharmaView is a biweekly educational and informative newsletter for improving readers’ marketing knowledge and reporting the latest news in the pharma industry. It also provides great opportunities to exchange ideas, network and be recognized among your peers in the industry.

Through PharmaView, you can:

Learn peer’s experience in pharma marketing

Stay in touch with what’s happening in pharmaceutical marketing today

Be on the pioneering edge of pharmaceutical marketing

Have networking / idea exchange opportunities

About Us 

Integrating local knowledge with international perspective, Consultech Co. Ltd. offers its clients and prospects one-lstop solutions with sales and marketing consultancy, advertising and promotion strategies.

Creative Design: Case study of Humira Visuals

Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX

Wyeth Pharmaceuticals, a division of Wyeth, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for new product enhancements for BeneFIX(R) Coagulation Factor IX (Recombinant) that will offer patients a simpler and more convenient preparation process compared with the original BeneFIX preparation process.

Mar 26, 2007

FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder

The U.S. Food and Drug Administration (FDA) today approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.

Mar 16, 2007

FDA Approves Tykerb for Advanced Breast Cancer Patients

The Food and Drug Administration (FDA) today approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

Mar 14, 2007

Positive Positioning: 10 steps to achieving standout

Uniqueness is the Holy Grail for marketers. Unique attributes can transcend cliches, giving products widespread respect. It's not always obvious what these traits might be, however. Charlene Prounis offers a guide to making your product stand out in the marketplace.

Feb 27, 2007

Ask the expert: How to… manage pharma’s mid-life crisis

Ideally, the lifecycle management of a brand is developed proactively, simultaneously with launch planning, which should forestall mid-lifecycle crises.

Mar 02, 2007

Sanofi split over possible Bristol merger

The disagreement concerns the Sanofi chairman Jean-Francois Dehecq who backs a transformational deal with Bristol, and the chief executive Gerard Le Fur who believes it is important to focus on Sanofi's internal research and development program.

Mar 28, 2007

Merck and Lundbeck end insomnia development program

Merck & Co. and Lundbeck have ended their joint development program for gaboxadol, an investigational new medicine for the treatment of insomnia currently in phase III development.

Mar 28, 2007

The Mystery Of Pfizer's Toxic Pill

Pfizer spent more than $900 million testing its experimental heart pill, torcetrapib. But in December a 15,000-patient study revealed that this chemical increased death rates, forcing Pfizer to suddenly drop the project.

Mar 26, 2007

Please feel free to offer your opinions and advices about PharmaView in order to better our services. Should you have any comments, or if you want to unsubscribe  from PharmaView, please send us an email: pharmaview@Consultech.com.cn  . Thank you!